Profusa Adopts NVIDIA-Powered Technology to Build AI-Driven Insight Portal for Continuous Biomarker Monitoring
Profusa (NASDAQ:PFSA), a digital health company, has announced the integration of NVIDIA technology to develop an AI-powered insight portal for continuous biochemistry monitoring. The portal will combine Profusa's Lumee鈩� oxygen monitoring system with NVIDIA NeMo to enable advanced clinical workflows.
The platform will feature an AI-driven physician portal with capabilities including EMR integration, remote monitoring, and a longitudinal health data graph that combines Profusa biomarkers with various health data sources. The system aims to provide real-time biochemistry monitoring and actionable clinical insights for healthcare providers.
Profusa plans to launch the portal in early 2026 across the European Economic Area (EEA) where CE Mark certification is accepted.
Profusa (NASDAQ:PFSA), azienda di digital health, ha annunciato l'integrazione della tecnologia NVIDIA per sviluppare un portale di insight basato su AI per il monitoraggio continuo della biochimica. Il portale unir脿 il sistema di monitoraggio dell'ossigeno Lumee鈩� di Profusa con NVIDIA NeMo per abilitare workflow clinici avanzati.
La piattaforma includer脿 un portale per medici guidato dall'AI con funzionalit脿 quali integrazione con EMR, monitoraggio remoto e un grafico longitudinale dei dati sanitari che combina i biomarcatori Profusa con diverse fonti di dati clinici. Il sistema punta a offrire monitoraggio biochimico in tempo reale e insight clinici azionabili per i professionisti sanitari.
Profusa prevede di lanciare il portale all'inizio del 2026 nell'Area Economica Europea (EEA), dove 猫 riconosciuta la marcatura CE.
Profusa (NASDAQ:PFSA), una compa帽铆a de salud digital, ha anunciado la integraci贸n de la tecnolog铆a NVIDIA para desarrollar un portal de insights impulsado por IA para la monitorizaci贸n continua de bioqu铆mica. El portal combinar谩 el sistema de monitorizaci贸n de ox铆geno Lumee鈩� de Profusa con NVIDIA NeMo para habilitar flujos de trabajo cl铆nicos avanzados.
La plataforma contar谩 con un portal para m茅dicos dirigido por IA con funciones como integraci贸n con EMR, monitorizaci贸n remota y un gr谩fico longitudinal de datos de salud que fusiona los biomarcadores de Profusa con diversas fuentes de datos sanitarios. El sistema pretende ofrecer monitorizaci贸n bioqu铆mica en tiempo real e insights cl铆nicos accionables para los proveedores de salud.
Profusa planea lanzar el portal a principios de 2026 en el 脕rea Econ贸mica Europea (EEA), donde se acepta la certificaci贸n CE.
Profusa (NASDAQ:PFSA), 霐旍韯� 項姢 旮办梾鞚� NVIDIA 旮办垹鞚� 韱淀暕頃� 歆�靻嶌爜鞚� 靸濏檾頃� 氇媹韯半鞚� 鞙勴暅 AI 旮半皹 鞚胳偓鞚错姼 韽劯鞚� 臧滊皽頃滊嫟瓿� 氚滍憸頄堨姷雼堧嫟. 鞚� 韽劯鞚� Profusa鞚� Lumee鈩� 靷办唽 氇媹韯半 鞁滌姢韰滉臣 NVIDIA NeMo毳� 瓴绊暕頃� 瓿犼笁 鞛勳儊 鞗岉伂頂岆毳� 歆�鞗愴暕雼堧嫟.
頂岆灚韽检潃 EMR 韱淀暕, 鞗愱博 氇媹韯半, Profusa 氚旍澊鞓る旎れ檧 雼れ枒頃� 瓯搓皶 雿办澊韯� 靻岇姢毳� 瓴绊暕頃� 膦呾爜(鞛リ赴) 瓯搓皶 雿办澊韯� 攴鸽灅頂� 霌� 旮半姤鞚� 臧栰稑 AI 旮半皹 鞚橃偓鞖� 韽劯鞚� 鞝滉车頃� 鞓堨爼鞛呺媹雼�. 鞚� 鞁滌姢韰滌潃 鞁れ嫓臧� 靸濏檾頃� 氇媹韯半瓿� 鞚橂歆勳澊 頇滌毄頃� 靾� 鞛堧姅 鞛勳儊 鞚胳偓鞚错姼毳� 鞝滉车頃橂姅 瓴冹潉 氇╉憸搿� 頃╇媹雼�.
Profusa電� CE 毵堩伂臧� 鞚胳爼霅橂姅 鞙犽熃瓴届牅歆�鞐�(EEA) 鞝勳棴鞐愳劀 2026雲� 齑� 韽劯鞚� 於滌嫓頃� 瓿勴殟鞛呺媹雼�.
Profusa (NASDAQ:PFSA), une entreprise de sant茅 num茅rique, a annonc茅 l'int茅gration de la technologie NVIDIA pour d茅velopper un portail d'insights aliment茅 par l'IA pour la surveillance continue de la biochimie. Le portail combinera le syst猫me de surveillance de l'oxyg猫ne Lumee鈩� de Profusa avec NVIDIA NeMo afin de permettre des workflows cliniques avanc茅s.
La plateforme proposera un portail m茅decin pilot茅 par l'IA avec des fonctionnalit茅s telles que l'int茅gration aux DSE, la surveillance 脿 distance et un graphe longitudinal des donn茅es de sant茅 qui associe les biomarqueurs Profusa 脿 diverses sources de donn茅es sanitaires. Le syst猫me vise 脿 fournir une surveillance biochimique en temps r茅el et des insights cliniques exploitables pour les professionnels de sant茅.
Profusa pr茅voit de lancer le portail d茅but 2026 dans l'Espace 茅conomique europ茅en (EEE), o霉 la marque CE est reconnue.
Profusa (NASDAQ:PFSA), ein Digital-Health-Unternehmen, hat die Integration von NVIDIA-Technologie angek眉ndigt, um ein KI-gest眉tztes Insight-Portal f眉r kontinuierliches Biochemie-Monitoring zu entwickeln. Das Portal wird Profusas Lumee鈩�-Sauerstoff眉berwachungssystem mit NVIDIA NeMo kombinieren, um erweiterte klinische Workflows zu erm枚glichen.
Die Plattform wird ein KI-gesteuertes 脛rzteportal bieten, das Funktionen wie EMR-Integration, Fern眉berwachung und eine longitudinale Gesundheitsdaten-Grafik enth盲lt, die Profusa-Biomarker mit verschiedenen Gesundheitsdatenquellen verkn眉pft. Ziel des Systems ist es, Echtzeit-Biochemie眉berwachung und verwertbare klinische Erkenntnisse f眉r Gesundheitsanbieter bereitzustellen.
Profusa plant, das Portal Anfang 2026 im Europ盲ischen Wirtschaftsraum (EEA) einzuf眉hren, wo die CE-Kennzeichnung anerkannt wird.
- Integration with industry leader NVIDIA's technology stack enhances platform capabilities
- Portal will enable real-time biochemistry monitoring and EMR integration
- Planned expansion into the European Economic Area (EEA) market in early 2026
- Development of unique proprietary dataset linking therapeutic decisions with real-time biochemistry changes
- Launch timeline extends to early 2026, indicating a significant wait for commercialization
- Initial rollout limited to EEA markets, excluding other major markets like the US
Insights
Profusa's NVIDIA partnership creates a powerful AI-driven biochemistry monitoring system with potential to transform personalized healthcare delivery by early 2026.
Profusa's new partnership with NVIDIA represents a strategic expansion of their biochemistry monitoring platform. By integrating NVIDIA's NeMo framework with their Lumee oxygen sensors, Profusa is positioning itself at the intersection of two rapidly evolving technologies: continuous biomarker monitoring and artificial intelligence.
The planned physician portal will deliver multiple clinical advantages:
- An LLM-powered assistant that integrates with existing electronic medical records
- Automated clinical workflows for treatment planning and remote monitoring
- A comprehensive health data graph that incorporates longitudinal biomarker data
- Built-in quality assessment and safety guardrails
What makes this development particularly significant is Profusa's unique ability to generate proprietary real-time biochemistry datasets across large populations. This data represents a missing piece in healthcare analytics that could potentially unlock new insights into treatment efficacy and disease management.
The commercialization timeline targeting early 2026 in the European Economic Area indicates Profusa is taking a methodical approach to regulatory approval, targeting markets where CE Mark certification provides a pathway to commercialization. This suggests the company has a clear regulatory strategy for this AI-enhanced platform.
From a technological perspective, this integration addresses a critical challenge in healthcare AI implementation: translating raw sensor data into clinically meaningful insights that can be seamlessly incorporated into physician workflows without adding to documentation burden.
Company expects early 2026 rollout in EEA; physician portal combines Lumee鈩� oxygen monitoring with NVIDIA NeMo to deliver AI-driven clinical workflows
BERKELEY, Calif, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Profusa, Inc. (鈥淧rofusa鈥� or the 鈥淐ompany鈥�) (Nasdaq: PFSA), a commercial stage digital health company pioneering a next-generation technology platform enabling the continuous monitoring of an individual鈥檚 biochemistry, announces the adoption of NVIDIA technology to power an AI-driven insight portal for continuous biochemistry monitoring.聽
鈥淲e believe that real-time biochemistry data across a large population is a data-set that is currently missing to enable the fulfillment of the promise of AI-enabled improvement in healthcare.聽 Profusa is uniquely positioned to provide this proprietary data set, linking therapeutic decisions with real-time biochemistry changes, to generate valuable insights that are lacking today.鈥� Ben Hwang, Ph.D., Profusa鈥檚 Chairman and CEO commented, 鈥淏y combining our Lumee platform with the industry leading NVIDIA NeMo hardware and software stack, we plan to build an AI-fueled, scalable technology backbone for better personalized sensor data accuracy and real-time sensor data connections with electronic medical records (EMR), facilitating treatment and outcome predictions, in addition to establishing a robust data base for clinical literature for disease management.鈥�
Expected capabilities and feature sets from the physician portal include:
- Agentic clinical workflows: A large language model (LLM) powered assistant for clinicians that integrates with EMRs, wearables, and home devices to assist with notes, orders, care plans, remote physiologic monitoring (RPM)/remote therapeutic monitoring (RTM), triage, and escalations聽聽
- Evaluation and monitoring: Built-in experimentation and metrics to assess assistant quality, drift, and safety over time
- Guardrails by design: Policy-aware orchestration to enforce clinical scope, data privacy, and safe responses across patient and provider experiences
- Model training options: From parameter-efficient tuning to post-training refinement of Profusa鈥檚 AI signal processing and clinical reasoning components
- Time-aligned health data graph: A longitudinal view that fuses Profusa biomarkers with EMR data (problems, meds, labs, vitals, imaging, notes), claims/pharmacy, wearables/IoT, genomics, and social determinants to power predictions and coaching
"We believe physicians need trustworthy, always-on insights, not more dashboards.聽 Our intention is for this cutting-edge portal technology to answer this need by translating raw optical signals into reliable biometrics, providing actionable clinical context.鈥� concluded Dr. Hwang.
The portal will be used in combination with Profusa鈥檚 Lumee oxygen optical hydrogel sensors and reader system, extending Profusa鈥檚 AI-enabled signal processing and care team tools from clinician offices to remote patient monitoring settings. Profusa expects an early 2026 rollout of the portal in the European Economic Area (EEA) 鈥攃onsisting of the EU, Lichtenstein, Norway, and Iceland -- which accepts the CE Mark.
About Profusa
Based in Berkeley, Calif., Profusa is a commercial stage digital health company led by visionary scientific founders, an experienced management team and a world-class board of directors in the development of a new generation of tissue-integrated sensors to detect and continuously transmit actionable, medical-grade data for personal and medical use. With its long-lasting, injectable and affordable biosensors and its intelligent data platform, Profusa aims to provide people with a personalized biochemical signature rooted in data that clinicians can trust and rely on.
鈥淟UMEE鈥�, 鈥淧ROFUSA鈥� and the PROFUSA logo are registered trademarks of Profusa Inc. in the United States, Canada, European Union, China, Japan, South Korea and Australia.
For more information, visit聽
Special Note Regarding Forward-Looking Statements
Certain statements in this press release (this 鈥淧ress Release鈥�) may be considered 鈥渇orward-looking statements鈥� within the meaning of the 鈥渟afe harbor鈥� provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or future financial or operating performance of Profusa or the combined company. In some cases, you can identify forward-looking statements by terminology such as 鈥渁nticipate,鈥� 鈥渂elieve,鈥� 鈥渃ontinue,鈥� 鈥渃ould,鈥� 鈥渆stimate,鈥� 鈥渆xpect,鈥� 鈥渇orecast,鈥� 鈥渇uture,鈥� 鈥渋ntend,鈥� 鈥渕ay,鈥� 鈥渕ight,鈥� 鈥減lan,鈥� 鈥減ossible,鈥� 鈥減otential,鈥� 鈥減redict,鈥� 鈥減roject,鈥� 鈥減ropose,鈥� 鈥渟eek,鈥� 鈥渟hould,鈥� 鈥渟trive,鈥� 鈥渨ill,鈥� or 鈥渨ould鈥� or the negatives of these terms or variations of them or similar terminology. Such forward-looking statements are subject to risks, uncertainties, and other factors which may be beyond the control of Profusa and could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Profusa and its management are inherently uncertain. Profusa cautions you that these statements are based on a combination of facts and factors currently known and projections of the future, which are inherently uncertain. There are risks and uncertainties described in the definitive proxy/final prospectus relating to the business combination, which has been filed with the SEC, and in other documents filed by Profusa from time to time with the SEC. These filings may identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Profusa cannot assure you that the forward-looking statements in this communication will prove to be accurate.
Contacts
Investor and Media Contacts
别尘补颈濒:听
phone:聽 1 (212) 655-0924
FAQ
What is Profusa's new AI-powered insight portal and when will it launch?
How will NVIDIA's technology enhance Profusa's monitoring platform?
What are the key features of Profusa's new physician portal?
Which markets will have access to Profusa's new monitoring platform?
How does Profusa's biochemistry monitoring technology work?
